Home / Health / Haemophilia Treatment Aims for Near-Normal Lives
Haemophilia Treatment Aims for Near-Normal Lives
1 Aug
Summary
- Haemophilia treatment now targets near-normal lives, not just preventing bleeds.
- Advances offer wider access to clotting factors and easier non-factor therapies.
- Awareness of disease and treatment options remains a significant gap.
The objective of haemophilia treatment has evolved, moving beyond the sole aim of preventing life-threatening bleeds to facilitating lives as close to normal as possible for individuals with this inherited bleeding disorder. Experts shared these insights at the National Haemostasis Update 2026, an annual scientific meeting. Significant treatment advancements over the past decade have dramatically improved patient outcomes and expectations.
Wider availability of clotting factors, alongside advancements in preventive therapy and novel non-factor treatments, means children with haemophilia can increasingly attend school regularly, engage in sports and social activities, and pursue careers and relationships without their condition defining them. These newer drugs are often longer-acting and administered via subcutaneous injections, offering greater convenience.
However, a critical gap remains in the awareness of haemophilia, its treatments, and the options available to patients. Experts emphasize the importance of moving towards home-based treatment, a norm in developed countries, allowing patients to receive care without arduous travel for every dose, provided they are stable on their regimen.
